Detalles de la búsqueda
1.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood
; 137(19): 2646-2656, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512419
2.
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Infection
; 50(4): 925-932, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35182355
3.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868632
4.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Br J Haematol
; 184(5): 760-768, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520013
5.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer
; 19(1): 504, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138244
6.
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.
Haematologica
; 102(8): 1432-1438, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28495913
7.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur J Haematol
; 99(1): 42-50, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370401
8.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer
; 16: 290, 2016 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114074
9.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica
; 100(7): 964-9, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25840597
10.
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood
; 119(4): 940-8, 2012 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160383
11.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Hematology
; 29(1): 2320006, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38407192
12.
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Lancet Oncol
; 13(12): 1250-9, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23168367
13.
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
Bone Marrow Transplant
; 58(11): 1182-1188, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37543712
14.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Hemasphere
; 7(7): e904, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427146
15.
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Haematologica
; 101(12): e485-e487, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27540135
16.
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Lancet Haematol
; 8(4): e267-e277, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667420
17.
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638344
18.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Leukemia
; 35(4): 1134-1144, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32694619
19.
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Cancer Chemother Pharmacol
; 61(5): 785-90, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17579865
20.
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Blood Adv
; 2(1): 1-9, 2018 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29344579